Table 1.
Characteristics of prospective cohort studies including patients with VTE.
| Name of cohort | Time period of patient recruitment | Country | Setting | Inclusion criteria | Identified publications |
|---|---|---|---|---|---|
| PHS: Physicians' Health study | 1982 to 1983 | USA | Male physicians residing in the United States | VTE; U.S. male physicians 40–84 years | (63) |
| DURAC trial: Duration of Anticoagulation study | April 1988 to April 1991 | Sweden | 16 secondary/ tertiary hospitals, Department of internal Medicine | First DVT/PE; age > 15 and <71 | (64) |
| LETS: Leiden Thrombophilia Study | January 1988 to December 1992 | Netherlands | 3 anticoagulation clinics | First DVT including arm thrombosis; age <70 | (52, 65, 66) |
| Padua* | January 1986 to June 1994 | Italy | Thrombosis unit of the University of Padua | First DVT | (67, 68) |
| Extended anticoagulation trial | October 1994 to April 1997 | Canada, USA | 13 secondary/tertiary hospitals | First unprovoked proximal; DVT/PE; received OAC ≥ 3 months | (69) |
| EPCOT: European Prospective Cohort on Thrombophilia study | March 1994 to September 1997 | Spain, Italy, Germany, UK, Netherlands, Sweden, France, Austria | 9 anticoagulation clinics | In this subcohort: First DVT/PE before study entry | (70) |
| LIST: The Linköping Study on Thrombosis | February 1998 to January 2000 | Sweden | Linköping University Hospital (emergency department) | VTE; age ≥ 18 | (71, 72) |
| THRIVE III: Ximelagatran in VTE | November 1999 to October 2000 | 18 countries: Europe, Argentina, Brazil, Canada, Israel, Mexico, South Africa | 142 secondary/tertiary hospitals | DVT/PE; age ≥ 18; received OAC for 6 months without recurrence | (17) |
| ELATE: The Extended Low-intensity Anticoagulation for unprovoked Thrombo-embolism | December 1998 to May 2001 | Canada, USA | 16 secondary/tertiary hospitals | Unprovoked proximal DVT/PE; received OAC ≥ 3 months; warfarin therapy during follow-up | (73) |
| CVTE: The Cambridge Venous Thromboembolism Study | August 1997 to January 2002 | United Kingdom | Addenbrooke's Hospital Cambridge (thrombosis center) | First DVT/PE | (44, 52, 74) |
| Bologna* | February 1995 to February 2002 | Italy | S. Orsola-Malpighi University Hospital Bologna (thrombosis center) | First DVT/PE; received OAC ≥ 3 months | (75–77) |
| Salamanca* | June 1997 to June 2002 | Spain | Thrombosis and Hemostasis Section of the University Hospital of Salamanca | First DVT/PE | (46) |
| PORtromb project: Oporto thrombophilia study | October 1997 to November 2002 | Portugal | Sao Joao University hospital (outpatients unit) | First DVT including arm thrombosis; age <40 | (45) |
| PREVENT: Prevention of Recurrent Venous Thromboembolism trial | July 1998 to December 2002 | USA, Canada, Switzerland | 52 secondary/tertiary hospitals | Documented unprovoked VTE; age ≥ 30; received OAC ≥ 3 month | (47) |
| Italy1* | May 1991 to April 2003 | Italy | Emergency departments of 3 secondary/tertiary hospitals | First proximal DVT/PE; received OAC 3–6 months without recurrence | (78, 79) |
| Italiy2*, AESOPUS investigators | January 1999 to July 2003 | Italy | 9 university or hospital centers in Italy | First proximal DVT; age ≥ 18; received OAC 3 months without recurrence | (80) |
| MEGA follow-up study: Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis | March 1999 to September 2004 | Netherlands | 6 anticoagulation clinics | First DVT/PE; age <70 | (53, 54, 81) |
| Florence | January 1999 to January 2007 | Italy | Thrombosis center at University hospital Careggi Florence | First VTE | (82) |
| Jordan* | January 2005 to December 2007 | Jordan | Jordan University Hospital | Acute PE | (83) |
| REVERSE I | 2001 to 2007 | Canada, France, Switzerland, USA | 12 tertiary care centers | First unprovoked proximal DVT/PE; age ≥ 18; received OAC 5–7 month without recurrence | (84, 85) |
| AUREC: Austrian Study on Recurrent Venous Thromboembolism | July 1992 to August 2008 | Austria | 4 thrombosis centers in Vienna; secondary care/tertiary care | First unprovoked DVT/PE; age ≥ 18; received OAC ≥ 3 months | (11, 16, 42, 43, 86–96) |
| MATS: Malmö Thrombophilia Study | March 1998 to December 2008 | Sweden | Skane University Hospital (emergency department) | VTE; age ≥ 18 | (10, 14, 37, 97–100) |
| TEHS-follow up study: Thromboembolism Hormone Study | 2003 to 2009 | Sweden | 43 secondary/tertiary hospitals | First DVT/PE; age > 18 and <64 | (39) |
| FARIVE study: Facteurs de risqué et de récidives de la maladie thromboembolique veineuse | 2003 to 2009 | France | 11 centers | First unprovoked DVT/PE; age ≥ 18 | (12, 36) |
| MAISTHRO: Main-Isar-Thrombosis registry | March 2000 to February 2010 | Germany | University hospital's outpatient department, Goethe University Hospital Frankfurt/Main | Acute or documented history of DVT/PE; age ≥ 18 | (38) |
| France* | January 1992 to June 2011 | France | Brest University Hospital | First DVT/PE; age ≥ 18 and <50; Women | (101, 102) |
| Madrid* | March 2004 to August 2013 | Spain | 2 University hospitals in Madrid | First unprovoked DVT/PE; age ≥ 18; received OAC ≥ 3 months | (103) |
| SWITCO65+: Swiss Venous Thromboembolism Cohort | September 2009 to December 2013 | Switzerland | 9 tertiary hospitals in Switzerland | First unprovoked DVT/PE; age ≥ 65 | (48) |
| Germany* | December 2008 to December 2018 | Germany | Multicenter | First VTE; age adolescents to 60 years | (40) |
| Egypt* | January 2015 to December 2020 | Egypt* | Tanta University Hospital | First VTE; age ≥ 18 | (41) |
| Conference Abstract I* | – | France | – | First proximal DVT/PE | (104) |
*
No cohort name available.